Articles related to LUNG CANCER

Discover how the FLAURA2 trial’s findings on combination therapy could revolutionize initial treatment plans for NSCLC patients with EGFR mutations. Learn more about the significant extension in progression-free survival and its potential clinical implications.

Discover how a novel combination therapy targeting EGFR and AXL proteins could revolutionize the treatment of head and neck squamous cell carcinoma and lung adenocarcinoma.

New data from the FLAURA2 trial suggests a promising but complex treatment landscape for EGFR-mutated advanced NSCLC. Physicians should weigh the significant PFS benefits against the increased risk of adverse events before considering this combination as a first-line treatment option.

New research questions the life-extending efficacy of most common cancer screenings, emphasizing the need for transparent physician-patient discussions to weigh the risks and benefits. Learn more about this crucial topic that might change your approach to recommending screenings.

Explore the phase 1 study findings on Divarasib, a covalent KRAS G12C inhibitor, which has shown durable clinical responses with a favorable safety profile in patients with KRAS G12C-positive tumors.

This phase 2 trial demonstrates the potential of perioperative nivolumab combined with chemotherapy in achieving higher pathological complete response and survival rates in stage III NSCLC. Explore the detailed findings to understand how this approach may influence future treatment paradigms.